YOU ARE HERE:
Pharmacokinetics news
page  of 4
 
Headline
Date
  Failure to suppress viral load more likely with nevirapine than efavirenz if ART started during TB treatment
19.11.07
  EACS: Once-a-day Kaletra can be risky
29.10.07
  ICAAC: No drug interactions found between TMC125 and ritonavir-boosted elvitegravir
21.09.07
  ICAAC: In NNRTI-based regimens, stepwise discontinuation minimises risk of antiretroviral resistance
19.09.07
  IAS: Studies present reassuring data on the use of ART in patients on TB treatment
23.07.07
  IAS: Botswanan study finds low concentrations of TB drugs common in HIV-positives, predict TB treatment failure
23.07.07
  Pfizer advises maraviroc dose increase if combined with etravirine
20.07.07
  Study suggests many children could have subtherapeutic levels of efavirenz
06.06.07
  CROI: Therapeutic concentrations of efavirenz, Kaletra, could be difficult to achieve in some children, with or without rifampicin
07.03.07
  Severe interaction between low-dose ritonavir and a blood pressure drug observed
12.12.06
  Merck buys protease inhibitor from Ambrilia, may be potent booster of other PIs
20.10.06
  Reduced dose of Kaletra soft-gel capsule effective in small study (corrected)
06.10.06
  Darunavir: negative interactions with Kaletra, Viagra and contraceptive pill reported
02.10.06
  Kaletra dose may need to rise in late pregnancy
26.09.06
  Rifampicin levels strongly reduced in patients with TB and diabetes
26.09.06
  Genetic marker predicts liver harm from nevirapine or efavirenz
12.09.06
  Ranbaxy presents bioequivalence data on two paediatric fixed dose triple combination tablets
17.08.06
  Acid-reducing agent increases saquinavir levels in HIV-negative volunteers
11.07.06
  Conflicting pharmacokinetic results when lopinavir and atazanavir are double-boosted with ritonavir
06.06.06
  HIV-positive children in UK and Ireland often given too low doses of antiretrovirals
19.05.06

page  of 4